Galderma Group AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	5,923	5,241	4,440	4,117
Revenue Growth (YoY)	13.01%	18.04%	7.85%	-
Cost of Revenue	1,809	1,632	1,355	1,232
Gross Profit	4,113	3,609	3,085	2,885
Selling, General & Admin	2,442	2,240	1,920	1,759
Research & Development	278	245	260	287
Other Operating Expenses	293	296	260	303
Total Operating Expenses	3,013	2,781	2,440	2,349
Operating Income	1,101	829	645	536
Interest Income	17	13	46	38
Interest Expense	-185	-203	-374	-564
Other Non-Operating Income (Expense)	8	0	-7	2
Total Non-Operating Income (Expense)	-160	-190	-335	-524
Pretax Income	939	638	310	11
Provision for Income Taxes	78	26	79	68
Net Income	863	613	231	-57
Net Income to Common	863	613	231	-57
Net Income Growth	40.78%	165.37%	-	-
Shares Outstanding (Basic)	234	236	238	238
Shares Outstanding (Diluted)	236	237	238	238
Shares Change (YoY)	-0.62%	-0.34%	0.10%	-
EPS (Basic)	3.68	2.60	0.97	-0.24
EPS (Diluted)	3.65	2.58	0.97	-0.24
EPS Growth	41.47%	165.98%	-	-
Free Cash Flow	1,080	1,072	360	44
Free Cash Flow Growth	0.75%	197.78%	718.18%	-
Free Cash Flow Per Share	4.59	4.52	1.51	0.19
Dividends Per Share	-	0.441	0.166	-
Dividend Growth	-	166.65%	-	-
Gross Margin	69.44%	68.86%	69.48%	70.08%
Operating Margin	18.59%	15.82%	14.53%	13.02%
Profit Margin	14.57%	11.70%	5.20%	-1.38%
FCF Margin	18.23%	20.45%	8.11%	1.07%
EBITDA	1,430	1,152	938	812
EBITDA Margin	24.14%	21.98%	21.13%	19.72%
EBIT	1,101	829	645	536
EBIT Margin	18.59%	15.82%	14.53%	13.02%
Effective Tax Rate	8.31%	4.08%	25.48%	618.18%